Bipolar Disorders · 2007 · 63 citations · 41 references
PharmacyPharmacotherapyPsychiatryAdult PsychiatryPsychiatric PharmacotherapyPsychopharmacologyBipolar Disorder PharmacotherapyBipolar DisordersMood Stabilizer TherapyStimulant TherapyWeight LossWeight ManagementAtypical Antipsychotic TreatmentBipolar Disorder DiagnosisBipolar MedicationBipolar Spectrum DisordersNegative Mood SymptomsTopiramate TherapyWeight Loss DrugWeight Loss Measurement
OBJECTIVES: Patients with bipolar disorder (BD) have an increased risk of obesity as well as psychotropic-associated weight gain. The objective of this study was to compare sibutramine and topiramate as adjunctive treatments for psychotropic-associated weight gain in overweight or obese outpatients with BD. METHODS: In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) > or =30 kg/m(2), or > or =27 kg/m(2) with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n = 18; 5-15 mg/day) or topiramate (n = 28; 25-600 mg/day). The primary outcome measure was weight loss. Secondary measures included changes in BMI, percent body weight loss, and mood symptoms. RESULTS: Patients randomized either to sibutramine or topiramate lost comparable amounts of weight (4.1 +/- 5.7 and 2.8 +/- 3.5 kg, respectively) and displayed similar rates of weight loss (0.85 and 0.82 kg/week, respectively). However, only four (22%) patients receiving sibutramine and six (21%) patients receiving topiramate completed the 24-week trial. In addition, the attrition patterns for the two drugs were different, with patients discontinuing topiramate doing so early in treatment and patients discontinuing sibutramine doing so throughout treatment. Also, higher ratings of manic and depressive symptoms significantly increased risk for early topiramate discontinuation compared to that for sibutramine. CONCLUSIONS: Adjunctive sibutramine and topiramate may have comparable weight loss effects in overweight or obese bipolar patients with psychotropic-associated weight gain, but are each associated with similarly high discontinuation rates. In addition, they may have different attrition profiles. Compared to sibutramine, discontinuation of topiramate may be more likely to occur early in treatment and may be more dependent upon manic and depressive symptoms.
41
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Robert C. Young, John T. Biggs, Vincent E. Ziegler et al. · The British Journal of Psychiatry · 1978 · 8.7K citations
Medicine, Neurology, Psychiatry +14
Excess Mortality in Bipolar and Unipolar Disorder in Sweden
Urban Ösby, Lena Brandt, N. Correia et al. · Archives of General Psychiatry · 2001 · 1.1K citations
Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease
Samuel Klein, Lora E. Burke, George A. Bray et al. · Circulation · 2004 · 928 citations
Medicine, Cardiology, Nutrition +17
The inventory for depressive symptomatology (IDS): Preliminary findings
A. John Rush, Donna E. Giles, Michael A. Schlesser et al. · Psychiatry Research · 1986 · 926 citations